---
layout: post
title: "医药生物行业周报：年报与季报进入密集披露期 关注估值性价比高的板块"
date: 2022-04-18 13:24:44 +0800
categories: pinganzhengquan
tags: 平安证券新闻
---
<p>平安观点：</p><p>行业观点：年报与季报进入密集披露期，关注景气度与估值性价比高的板块。进入4 月，2021 年报与2022 一季报密集披露。在这个时间点我们建议关注<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>增长确定性强，业绩环比增长改善明显的企业。其中，前期跌幅较大的CXO 板块，业绩确定性较强，且未来仍然具备较好的成长性，目前估值性价比凸显。<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>板块中的一些优质企业，基本面稳健，且近期<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>利好政策频出。随着<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>企业业绩的逐步释放，考虑板块估值，在此时点仍然值得关注。</p><p>投资策略：主线一：新冠口服药相关产业链，日内瓦药品专利池组织(MPP)先后宣布授权国内8 家药企生产<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>与默克的新冠特效药，相关新冠药生产及产业链企业的业绩表现有望受益，建议关注：<span id="stock_1.600521"><a href="http://quote.eastmoney.com/unify/r/1.600521" class="keytip" data-code="1,600521">华海药业</a></span><span id="quote_1.600521"></span>、<span id="stock_0.000739"><a href="http://quote.eastmoney.com/unify/r/0.000739" class="keytip" data-code="0,000739">普洛药业</a></span><span id="quote_0.000739"></span>、复星药业、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>、<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_0.002453"><a href="http://quote.eastmoney.com/unify/r/0.002453" class="keytip" data-code="0,002453">华软科技</a></span><span id="quote_0.002453"></span>、<span id="stock_0.300233"><a href="http://quote.eastmoney.com/unify/r/0.300233" class="keytip" data-code="0,300233">金城医药</a></span><span id="quote_0.300233"></span>、歌礼制药和<span id="stock_0.300584"><a href="http://quote.eastmoney.com/unify/r/0.300584" class="keytip" data-code="0,300584">海辰药业</a></span><span id="quote_0.300584"></span>等。主线二：中医药板块，重磅支持政策不断，政策落地提升信心。品牌OTC 中药具有自主定价权，其它中成药集采降价温和，板块整体估值性价比高，建议关注：<span id="stock_1.600422"><a href="http://quote.eastmoney.com/unify/r/1.600422" class="keytip" data-code="1,600422">昆药集团</a></span><span id="quote_1.600422"></span>、<span id="Info.116.02273"><a href="http://quote.eastmoney.com/unify/r/116.02273" class="keytip" data-code="116,02273">固生堂</a></span>、<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>。主线三：创<span id="stock_0.300832"><a href="http://quote.eastmoney.com/unify/r/0.300832" class="keytip" data-code="0,300832">新产业</a></span><span id="quote_0.300832"></span>链，CXO 维持高景气度且估值触底，结合估值以及政策、资金因素，我们更倾向于CDMO 和大分子CXO 赛道，建议关注：</p><p><span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>。主线四：在上述三条主线外，还存在一些其他高景气、高壁垒的赛道：包括特色原料药、制剂出口与核医学等。建议关注：<span id="stock_1.603520"><a href="http://quote.eastmoney.com/unify/r/1.603520" class="keytip" data-code="1,603520">司太立</a></span><span id="quote_1.603520"></span>、<span id="stock_0.300497"><a href="http://quote.eastmoney.com/unify/r/0.300497" class="keytip" data-code="0,300497">富祥药业</a></span><span id="quote_0.300497"></span>、<span id="stock_0.300702"><a href="http://quote.eastmoney.com/unify/r/0.300702" class="keytip" data-code="0,300702">天宇股份</a></span><span id="quote_0.300702"></span>、<span id="stock_0.002675"><a href="http://quote.eastmoney.com/unify/r/0.002675" class="keytip" data-code="0,002675">东诚药业</a></span><span id="quote_0.002675"></span>、<span id="stock_1.603707"><a href="http://quote.eastmoney.com/unify/r/1.603707" class="keytip" data-code="1,603707">健友股份</a></span><span id="quote_1.603707"></span>、<span id="stock_0.300630"><a href="http://quote.eastmoney.com/unify/r/0.300630" class="keytip" data-code="0,300630">普利制药</a></span><span id="quote_0.300630"></span>、<span id="Info.116.00512"><a href="http://quote.eastmoney.com/unify/r/116.00512" class="keytip" data-code="116,00512">远大医药</a></span>。</p><p>行业要闻荟萃：1)<span id="stock_106.BMY"><a href="http://quote.eastmoney.com/unify/r/106.BMY" class="keytip" data-code="106,BMY">百时美施贵宝</a></span><span id="quote_106.BMY"></span>CAR-T 疗法Breyanzi(liso-cel)在欧盟获批，用于治疗大B 细胞淋巴瘤(LBCL)；2)拜耳的larotrectinib 在中国获批，用于治疗携带 NTRK 融合基因的实体瘤成人和儿童患者；3)CGOncology 公司溶瘤病毒/PD-1 抗体组合2 期临床结果积极；4)<span id="Info.116.06160"><a href="http://quote.eastmoney.com/unify/r/116.06160" class="keytip" data-code="116,06160">百济神州</a></span>百悦泽在慢性淋巴细胞白血病中对比伊布替尼取得总缓解率有优效性。</p><p>行情回顾：上周A 股医药板块下跌1.38%，同期<span id="Info.3261"><a href="http://quote.eastmoney.com/unify/r/1.000300" class="infokey">沪深300</a></span> 指数下跌0.99%，医药行业在28 个行业中排名第11 位。上周H 股医药板块下跌2.45%，同期恒生综指下跌1.16%，医药行业在11 个行业中排名第11 位。</p><p>风险提示：1)政策风险：医保控费、药品降价等政策对行业负面影响较大；2)研发风险：医药研发投入大、难度高，存在研发失败或进度慢的可能；3)公司风险：公司经营情况不达预期。</p><p class="em_media">（文章来源：平安<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204182346612994>

[返回平安证券新闻](//finews.withounder.com/category/pinganzhengquan.html)｜[返回首页](//finews.withounder.com/)